東北製藥(000597.SZ):子公司齊多拉米雙夫定片獲得藥品註冊證書
格隆匯9月13日丨東北製藥(000597.SZ)公佈,近期,公司全資子公司東北製藥集團瀋陽第一製藥有限公司(“第一製藥”)收到國家藥品監督管理局核准簽發的《藥品註冊證書》。藥品名稱為齊多拉米雙夫定片。
齊多拉米雙夫定片由葛蘭素史克開發,商品名為Combivir(雙汰芝)。該品於1997年9月首次在美國上市,於1998年在歐盟上市,原研產品雙汰芝已批准國內進口。該品單獨或與其他抗逆轉錄病毒藥物聯合使用,用於治療人類免疫缺陷病毒(HIV)感染。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.